First patients included in our clinical investigations8. April 2022
InnoCon Medical will participate in the ICS 2022 Vienna13. August 2022
The Innovation Fund Denmark and Avisen Danmark have both published an article regarding our project UCon. Additionally, 14 regional/local newspapers in Denmark have picked up the story. The articles describe the problem regarding incontinence. Many suffer in silence, and studies show that every fifth adult in Denmark can experience it. In many cases, people suffering experience low quality of life. However, our new device UCon has been approved for clinical trials and will hopefully benefit a large group of patients. UCon is expected to be CE marked early 2024. Four Danish doctors, Peter Christensen, and Jakob Duelund-Jakobsen from Aarhus Universitetshospital, Niels Klarskov from Herlev Hospital, and Niels Qvist from Odense Universitetshospital are involved in the development of UCon, and 40 selected patients from all over Denmark will test UCon for a month. The Innovation Fund Denmark is supporting the project with 6.5 million DKK. Peter Christensen, professor & colorectal surgeon from Aarhus Universitetshospital, has been interviewed for the articles and states the following: "If UCon works, it means that some patients will find a working solution, instead of suffering many uncontrolled toilet visits a day together with frequent incontinence episodes." Christensen also highlights that current neurostimulation treatments are expensive & invasive, and UCon has the potential to fill a gap in the field of incontinence treatments: "UCon accesses the relevant nerves and offers an easily accessible and affordable solution that does not require surgery.". He continues: "With the new UCon product from InnoCon Medical, it will probably be possible for us to lower the indications for offering neurostimulation as treatment, and thereby help more patients." We, together with our clinical partners, look forward to the results of the clinical trials and hope UCon can offer a desirable treatment option for many patients in need. Enrollment for the clinical study is going well, here in June we are halfway as planned.